Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Annals of Hematology
Eirini KatodritouEvangelos Terpos

Abstract

We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical relapse on PFS in 207 consecutive myeloma patients treated with Len/Dex in second line, according to routine clinical practice in Greece. First-line treatment included bortezomib-based (63.3%) or immunomodulatory drug-based (34.8%) therapies; 25% of patients underwent autologous stem cell transplantation. Overall response rate was 73.4% (17.8% complete response and 23.7% very good partial response); median time to best response was 6.7 months. Overall, median PFS and 12-month PFS rate was 19.2 months and 67.6%, respectively. 67.5% of patients had biochemical relapse and 32.5% had clinical relapse prior to initiation of Len/Dex. Median PFS was 24 months for patients treated at biochemical relapse vs. 13.2 months for those treated at clinical relapse (HR:0.63, p = 0.006) and the difference remained significant after adjustment for other prognostic factors. Type of relapse was the strongest prognostic factor for PFS in multivariate analysis. These real-world data confirm the efficacy of Len/Dex combination at first ...Continue Reading

References

Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Feb 5, 2011·Leukemia·M A DimopoulosUNKNOWN European Myeloma Network
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Aug 2, 2013·The New England Journal of Medicine·María-Victoria MateosJesús-F San Miguel
Sep 4, 2014·The New England Journal of Medicine·Lotfi BenboubkerUNKNOWN FIRST Trial Team
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Apr 4, 2015·Blood·Ajay K NookaSagar Lonial
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators

❮ Previous
Next ❯

Citations

Jan 22, 2019·American Journal of Hematology·Rajshekhar ChakrabortyJason Valent
Mar 15, 2021·Clinical Lymphoma, Myeloma & Leukemia·Ioannis Ntanasis-StathopoulosMeletios A Dimopoulos
Mar 17, 2021·Hematological Oncology·Teruhito TakakuwaItaru Matsumura

❮ Previous
Next ❯

Methods Mentioned

BETA
ISS

Software Mentioned

LEGEND
SAS

Related Concepts